Sanofi (France)
NEWS
This approval marks the first time in a decade Sanofi has had a wholly-owned cancer drug approved.
The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.
It was another busy week for clinical trial updates. Here’s a look.
No treatments are currently approved for the disease.
The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Despite having one of the best-selling insulin products on the market, Sanofi is exiting diabetes and cardiovascular research and development in favor of more lucrative areas, particularly cancer research.
Similar to the Biotech Bay list, BioSpace takes a look at the top 10 2019 Life Sciences Ideal Employer Report’s for Genetown.
Sanofi announced it is acquiring Synthorx for $68 per share in cash, a value of $2.5 billion. The deal has been unanimously approved by both companies’ boards.
JOBS
IN THE PRESS